Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Niraparib-Bevacizumab · 1 trial · 1 indication
To determine the clinical effectiveness of the study treatment assessed using progression free survival(6months) according to RECIST v1.1 criteria (Investigator determined)
| Arm | Type | Description |
|---|---|---|
| experimental | EXPERIMENTAL | Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous |
| Name | Type | Description |
|---|---|---|
| Niraparib-Bevacizumab | DRUG | Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W) \*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD. |
\## Inclusion Criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant has a histologically confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed Müllerian carcinoma with a high-grade serous com...